Navigation Links
Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease
Date:10/19/2010

SAN DIEGO, Oct. 19 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

The launch of Phase 2 follows a fully enrolled Phase 1 portion that demonstrated early safety using an enhanced CERE-120 dosing regimen targeting the substantia nigra and putamen, two brain areas especially affected by Parkinson's disease. This study is enrolling at 11 major medical centers throughout the United States and includes investigators Drs. Mark Stacy and Dennis Turner at Duke University School of Medicine, Drs. Catherine Cho and Ron Alterman at Mount Sinai Medical Center, New York, and Drs. Stewart Factor and Nicholas Boulis at Emory University Hospital, who were all involved in treating the patients in the Phase 1 portion of this study.

Additional clinical sites include Columbia University Medical Center, NYC, NY; Beth Israel Medical Center, NYC, NY; University of Pennsylvania Hospital, Philadelphia, PA; University of Alabama, Birmingham, AL; Rush University Medical Center, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, San Francisco, CA and Stanford University School of Medicine, Palo Alto, CA.

Details on the clinical study can be found at www.ceregene.com or www.clinicaltrials.gov/ct2/show/NCT00985517.

This Phase 2b clinical study is partially funded by a $2.5M LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) award from The Michael J. Fox Foundation for Parkinson's Re
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
2. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
3. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
4. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
5. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
6. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
7. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
8. Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
9. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
10. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
11. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Nanomix Inc., (Nanomix), a ... of mobile diagnostic tests to enable earlier ... pre-hospital settings, today announced it has received ... certification was awarded by the British Standards ... certification bodies. ISO 13485:2003 ...
(Date:11/26/2014)... 2014  Breckenridge Pharmaceutical, Inc. announced today that ... with Pii (Pharmaceutics International, Inc.) ( Hunt ... Pii expect to develop and commercialize several new ... will develop, manufacture and supply the products, and ... its own label.  The drugs, comprised of four ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Jaffray Healthcare Conference in New York ... PDT . Dr. Helen Torley , President and ... The presentation will be webcast through the "Investors" section of ... will be made available for 90 days following the event. ...
Breaking Medicine Technology:Nanomix Receives ISO 13485:2003 Certification 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... , RIVIERA BEACH, Fla., Dec. 14 Perry Baromedical, international ... launch of the Sigma Elite, with extended patient data capture ... on each monoplace chamber model currently available ( www.perrybaromedical.com ) ... "Smart Hyperbaric System" includes: , Data Capture Via Computerized ...
... Dec. 14 Sword Diagnostics, Inc. is pleased to ... has issued patent number 7,599,057 titled "Method and Apparatus ... the company. The patent covers the core technology which ... this patent supports the underlying strategy as we move ...
Cached Medicine Technology:Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability 2
(Date:11/27/2014)... DressVe , the well-known trendy young women’s clothing retailer, has ... Nov. 29 – Dec. 3 2014. In the special offer, ... 90% off. In addition, free delivery is provided for the ... , Dresses that combine trendy styles and high quality ... and figure. The designers of DressVe.com know this point very ...
(Date:11/27/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... , Firstly, the report provides a basic overview of ... Then, the report explores the international and Chinese major ...
(Date:11/27/2014)... November 28, 2014 The American Society for ... social media campaign in honor of World AIDS Day 2014. ... tested. Find a cure.” icon and infographic designed to generate ... getting tested for HIV. , ASCP has asked members to ... “Give a minute. Get Tested. Find a cure.” icon and ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
(Date:11/27/2014)... 2014 In a world enveloped ... sleep has lessened, and due to the intrusion ... of sleep has eroded. According to Web MD, ... job (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This remarkably high ... an incalculable amount, leading not only to dissatisfied ...
Breaking Medicine News(10 mins):Health News:DressVe.com Introduces Its 2014 Special Monday Sales To The Global Customers 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3Health News:ASCP Launches Social Media Campaign in Honor of World AIDS Day 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2
... of people are disappointed that the condom has not served ... sex, which defeats the goal of using condoms. ... for the FPA, Family Planning association, and the findings revealed ... reasons for ineffective use of condoms. As much as 43% ...
... the US U.S. doctors often misdiagnose tuberculosis due to ... suffer for years.// ,Tuberculosis is among the ... to the World Health Organization, has taken the lives ... tuberculosis bacterium has the ability to remain dormant for ...
... air sterilization technology that the U.S. Department of Defense ... may be protecting hospital patients from deadly infections, thanks ... of Science, Technology and Academic Research (NYSTAR). ,The ... becoming increasingly difficult to treat, are on the rise. ...
... known; a bite on the body that allows the virus ... happens next that causes the virus //to multiply and take ... Medical Institute (HHMI) international scholar in Argentina have been able ... virus multiply, which is the main cause of the potentially ...
... by the stem cells researchers across the world and ... Illumina Inc., it was found that embryonic stem cell ... totipotent. ,This sets aside the embryonic stem ... These characteristics could be later used to replace diseased ...
... Treatment Trial (NETT) it was found that emphysema patients ... ,The bilateral lung volume reduction surgery (LVRS) to ... among these patients. NETT researchers describe the effects of ... 4.3 years, two years longer than the primary results ...
Cached Medicine News:Health News:Doctors In US Lack Skills For The Diagnosis Of TB 2Health News:Device Can "Battle" Hospital Infections 2Health News:Device Can "Battle" Hospital Infections 3Health News:The Dengue Virus Unplugged 2Health News:The Dengue Virus Unplugged 3Health News:Human Embryonic Stem Cells Could Be Later Used In Therapeutic Cloning 2
The K-ASSAY Anti-Streptolysin O Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifyi...
Eppendorf expands its line of benchtop microcentrifuges with the 5418. This easy-to-use microcentrifuge features a certified aerosol-tight rotor and a unique, contoured rotor bowl design to reduce no...
... The Directigen EZ Flu A+B test ... direct and qualitative detection of influenza A ... and throat swabs of symptomatic patients. The ... differentiated test, such that influenza A viral ...
... Mid-Urethral Sling System is intended to ... sling for the treatment of stress ... an innovative mid-urethral sling that offers ... all of which are designed to ...
Medicine Products: